FDA Approves Merck ’s Keytruda (pembrolizumab) in Combination With Inlyta (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)

KENILWORTH, N.J.--(BUSINESS WIRE)--April 22, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news